Stockwinners Market Radar for April 11, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EDT Axon launches next generation body camera - Axon introduced its next generation body-worn camera, Axon Body 4. Key upgrades include expanded communications ability, more points of view, and upgraded camera features.

20:04 EDT Cathie Wood's ARK Investment sold 63.4K shares of DraftKings today

18:54 EDT HF Foods Group adopts limited duration stockholder rights plan - HF Foods Group announced that the Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of the company's common stock to stockholders of record as of the close of business on April 24. The Board adopted the Rights Plan out of concern that parties may be engaging in undisclosed stock accumulation and group formation activities to gain control of HF Foods, depriving stockholders of both the opportunity to realize the full value of their investment in the company and the opportunity to determine the future course of the company. The Board has not initiated a process to sell the company. The Board believes that the company has excellent standalone prospects and that its current strategic plan is creating and unlocking significant value for all stockholders. The Rights Plan has a 365-day term, expiring on April 11, 2024.

17:55 EDT Southern Company CEO sells $3.58M in common stock - In a regulatory filing, Southern Company disclosed that its CEO Thomas Fanning sold 50K shares of common stock on April 10th in a total transaction size of $3.58M.

17:35 EDT InterPrivate IV InfraTech Partners to redeem its public shares - InterPrivate IV InfraTech Partners announced that it will redeem all of its issued and outstanding shares of Class A common stock, because the Company's sponsor has determined that it will not make an additional contribution to the Company's trust account required in order to further extend the April 9 deadline under the Company's Amended and Restated Certificate of Incorporation for the Company to complete an initial business combination. Following such redemption of the Public Shares, the Company will liquidate and dissolve in accordance with the provisions of the Charter. The Company anticipates that the Public Shares will cease trading at or around the close of business on April 12. The Redemption Amount is expected to be paid by April 25 to holders of Public Shares outstanding at the close of business on April 12 without any required action on their part. On the Redemption date, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount. After April 25 the Company will cease all operations except for those required to wind up the Company's business. The Company's warrants will expire in accordance with their terms upon the liquidation of the Company. The Company expects that The Nasdaq Stock Market will file a Form 25 with the Commission to delist its securities.

17:31 EDT GigCapital5 announces transfer of listing to Nasdaq - GigCapital5 announced that it intends to move the listing of its common stock from the New York Stock Exchange to The Nasdaq Global Market on or around April 26, 2023. While the GigCapital5 Common Stock will be listed for trading at Nasdaq, the units and warrants of GigCapital5 will trade at the OTC Markets Group Inc. The decision to list on Nasdaq was made in consideration of the proposed business combination of GigCapital5 with QT Imaging, Inc. and will enable the post-combination company to be listed alongside the other innovative technology companies that are also listed on Nasdaq. GigCapital5 expects the GigCapital5 Common Stock to commence trading on Nasdaq on or about April 26, 2023 under the symbol "GIA".

17:14 EDT Reborn Coffee to focus on increasing sales and growing average unit volumes - "Looking ahead, we continue to focus on increasing our customer base and sales and growing Average Unit Volumes at our existing stores. New innovative products like our Cascara and Super-Premium ice cream will help to build additional revenue, differentiate our brand, and broaden our reach beyond our retail locations into B2B and DTC sales. Internationally we are positioning Reborn for rapid expansion in new key markets and developing our franchise opportunity. Taken together, we believe we are well positioned to reach our goals for sustained operational execution and year-over-year revenue growth. We enter 2023 in a strong position and look forward to sharing our accomplishments as we strive to create value for our shareholders, customers, and employees," concluded Kim.

17:02 EDT Avista signs agreement with Pine Creek RNG to purchase renewable gas - Avista recently signed an agreement with Pine Creek RNG to purchase renewable natural gas, or RNG, to be produced from projects in Richland, Washington and Waterloo, Iowa. In October 2022, Avista released a request for proposal, or RFP, to secure RNG resources for its customers over the long term. RNG is derived from organic waste streams that would otherwise release methane to the environment as they decompose. These sources include, for example, landfills, wastewater treatment plants and food waste. RNG is produced by capturing that methane that would otherwise escape to the atmosphere and purifying it to make it very similar to conventional natural gas. Some of Pine Creek's projects include the Horn Rapids Landfill owned by the City of Richland and Lamb Weston's potato processing plant in Richland. Construction is expected to be complete in both projects by the end of 2023 and produce 2.5M therms of RNG annually, which is equivalent to the natural gas used by approximately 4,173 Washington homes each year. In early 2024, a project at the Black Hawk County Landfill in Waterloo, Iowa is expected to begin producing 2.6M therms annually.

17:02 EDT Eucrates Biomedical Acquisition announces liquidation - Eucrates Biomedical Acquisition Corp. announced the following: The Company anticipates that it will not be able to consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association; Accordingly, the company intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association; As part of that dissolution and liquidation, the company will redeem all of the outstanding ordinary shares that were included in its initial public offering at a per-share redemption price of approximately $10.00. As of the close of business on April 26, 2023, the Public Shares will represent the right to receive the redemption amount. Upon redemption such Public Shares will be deemed cancelled. In order to provide for the disbursement of funds from the trust account, the company has instructed the trust account's trustee to take all necessary actions to liquidate the trust account. The trust account's proceeds will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares.

16:46 EDT Cohen & Steers reports preliminary AUM $79.9B as of March 31 - A decrease of $3.6B from assets under management at February 28. The decrease was due to market depreciation of $2.6B, net outflows of $700M and distributions of $318M.

16:33 EDT Cellectis announces first patient dosed with UCART22 in France - Cellectis announced that the first patient in Europe has been dosed in France with its in-house manufactured product candidate UCART22 and completed the 28-day Dose Limiting Toxicity period.

16:21 EDT Latch receives extension from Nasdaq - Latch announced that on April 5, the company received a decision from a Nasdaq Hearings Panel granting the company's request for continued listing on the Nasdaq Global Select Market, subject to the company demonstrating compliance with Nasdaq Listing Rule 5250 on or before August 4 and certain other conditions. As previously disclosed, the company received delisting notifications from the Listing Qualifications Department of Nasdaq following the company's failure to timely file its quarterly reports on Form 10-Q for the quarterly periods ended June 30, 2022 and September 30, 2022 with the Securities and Exchange Commission.

16:16 EDT Procter & Gamble raises quarterly dividend to 94.1c per share from 91.3c - The dividend is payable on or after May 15, 2023 to Common Stock shareholders of record at the close of business on April 21, 2023.

16:12 EDT Varonis opens Australia data center to support clients moving to SaaS offering - Varonis Systems announced the opening of its first data center in Australia to support customers moving to Varonis' SaaS offering. The new data center, located in Sydney, will help Varonis customers demonstrate compliance with national data sovereignty rules and enable them to leverage Varonis' world-class visibility, automation, and support. The new data center will help Varonis meet growing demand from the local market at a time when Australian companies have been hit hard by a relentless wave of ransomware attacks and proposed Australian Privacy Act amendments place increased scrutiny and potential data breach fines on organizations that fail to protect personal information."After doubling our team in the past year, Varonis is proud to announce we are positioned for further growth with our new data center in Australia, which opens the door for organizations interested in adopting Varonis' SaaS offering," said Varonis Vice President of APAC Scott Leach. "Privacy-minded companies can be assured data is kept locally while they benefit from everything our SaaS platform brings to the table - from classifying critical data and slashing exposure to putting a stop to threats such as ransomware and insider attacks - automatically and with minimal effort."

16:10 EDT ClearPoint Neuro extends license and research pact with Philips - ClearPoint Neuro announced further expansion of its worldwide license and research agreement with Philips, a firm in health technology, to add subnuclei segmentation applied to MRI, and potentially CT scans, for use in the operating room. The design goal of the ClearPoint Maestro Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning. "Extending our software collaboration with Philips beyond the subcortical brain regions in Maestro to include segmentation of subnuclei from MRI is key to our planned expansion into the operating room," commented Joe Burnett, President and CEO of ClearPoint Neuro. "ClearPoint has built our brand based on our unique suite of MRI Guidance hardware and software and with more than 10 years of experience and 6,000 cases, we have learned a lot under challenging conditions. We continue our progression as a platform neuro-navigation company by leveraging what we have learned in the MRI and applying that learning to other surgical arenas in the hospital. This new agreement with Philips will optimize the computational speed of Maestro and enable the fully automatic segmentation of clinically approved deep brain stimulation targets including the globus pallidus internus the subthalamic nucleus the ventral intermedius nucleus and the anterior nucleus of the thalamus . DBS targets planned in the space of a pre-op MRI can be mapped to plans in an operating room surgical environment using other interventional modalities like CT. This will allow surgeons to select which patients benefit from CT compared to MRI based on their presentation, but still take advantage of many unique and valuable features of the ClearPoint platform."

16:06 EDT Amtech Systems announces multiple orders for horizontal diffusion furnace system - Amtech Systems "announced multiple orders for fully automated clustered 300mm horizontal diffusion furnace systems used in power semiconductor manufacturing. These orders, valued at $9.7 million, will ship mid fiscal year 2024. Horizontal diffusion furnaces are particularly suited for 300mm power semiconductor fabrication, offering higher process temperatures and superior prevention of wafer slippage. The systems will be installed in leading semiconductor IDM and foundry fabs in North America and Asia."

14:59 EDT Musk says April 20 final date for removing legacy Blue checks - Elon Musk tweeted: "Final date for removing legacy Blue checks is 4/20" Reference Link

14:21 EDT Canadian Solar subsidiary CSI Solar updates capacity plans - Canadian Solar announced its majority-owned subsidiary CSI Solar 2024 capacity expansion plans. Namely, by the end of Q1 2024, CSI Solar intends to add 30 GW of ingot, 15 GW of wafer, 10 GW of cell and 25 GW of module capacity. Capacity expansion plans are subject to change without notice based on market conditions and capital allocation plans. Dr. Shawn Qu, Chairman and CEO of Canadian Solar, commented, "All our new capacity additions for 2023 and 2024 will be in the latest N-type technology, enabling us to better meet strong market demand and accelerate growth. In addition, by increasing the level of vertical integration, we continue to improve our control over technology, raw material sources and costs. These business plans will hep us further strengthen our long-term leadership position not just across our end markets but also throughout our supply chain positioning."

13:39 EDT Google TV introducing new live TV experience with over 800 free channels - Google's Nick Staubach stated in Keyword blog post: "These days we have more ways to stream movies and TV shows than ever - but as streaming services multiply, so do our monthly bills. Luckily, there's been an increase in the number of free TV options available, offering everything from local news and popular shows to hit movies. But with all the choices out there, it can be hard to know what's available and how to find it. That's where Google TV comes in. Today, we're introducing a new live TV experience that lets you browse more than 800 free TV channels across multiple providers, organized in one easy-to-use guide right in the Live tab. Starting today, we're integrating access to free channels from Tubi, Plex and Haystack News directly into the Live tab, alongside the existing lineup of channels from Pluto TV. We're also launching free built-in channels from Google TV that you can watch without even downloading or launching an app." Reference Link

13:02 EDT HII awarded $567.6M subcontract modification from General Dynamics Electric Boat - HII (HII) announced that its Newport News Shipbuilding division has been awarded a $567.6M subcontract modification from General Dynamics Electric Boat (GD) to provide long-lead-time material and advance construction activities for Columbia-class ballistic missile submarines. HII is currently under contract for construction of submarine modules for Build I, the first two submarines in the class: District of Columbia and Wisconsin. The advance procurement funds from this subcontract modification, awarded April 4, will allow NNS to purchase major components and commodity material and to begin advance construction on Build II, the next five submarines in the class, the company said. "This contract modification underscores the critical manufacturing work our shipbuilders do for the U.S. Navy, as major contributors to the Columbia-class," said Brandi Smith, NNS vice president for Columbia-class construction.

12:38 EDT Walmart announces closure of four Chicago stores - Walmart stated in a post to its corporate newsroom: "Today we have made the difficult decision to close four of our stores in Chicago. The decision to close a store is never easy. The impact is greater than just closing a building. It affects people - people who work in, shop in and live in communities near our stores - and we never take that lightly. Treating people and communities with respect and compassion during this transition will guide everything we do... We know the community will have questions about why we are closing these locations. The simplest explanation is that collectively our Chicago stores have not been profitable since we opened the first one nearly 17 years ago - these stores lose tens of millions of dollars a year, and their annual losses nearly doubled in just the last five years. The remaining four Chicago stores continue to face the same business difficulties, but we think this decision gives us the best chance to help keep them open and serving the community. Over the years, we have tried many different strategies to improve the business performance of these locations, including building smaller stores, localizing product assortment and offering services beyond traditional retail. We have invested hundreds of millions of dollars in the city, including $70 million in the last couple years to upgrade our stores and build two new Walmart Health facilities and a Walmart Academy training center. It was hoped that these investments would help improve our stores' performance. Unfortunately, these efforts have not materially improved the fundamental business challenges our stores are facing." Reference Link

12:01 EDT Microsoft, EE agree to 10-year cloud gaming partnership - Microsoft Gaming (MSFT) CEO Phil Spencer announced that the Xbox maker and EE are expanding their partnership with a 10-year commitment in cloud gaming to bring PC games built by Activision Blizzard (ATVI), following the acquisition, and Xbox to EE customers. "We are committed to bring more games to more people, however they choose to play," Spencer said. Reference Link

12:00 EDT Signa Sports falls -6.9% - Signa Sports is down -6.9%, or -26c to $3.53.

12:00 EDT BP Prudhoe Bay rises 14.2% - BP Prudhoe Bay is up 14.2%, or 91c to $7.31.

12:00 EDT Brookdale Senior Living rises 33.4% - Brookdale Senior Living is up 33.4%, or 99c to $3.98.

11:46 EDT Meta says people in Brazil can pay local small businesses directly in WhatsApp - Mark Zuckerberg announced that people across Brazil can pay local small businesses right within a WhatsApp chat, Meta Platforms (META), the parent of WhatsApp, reported in a post to its newsroom. "This seamless and secure checkout experience will be a game-changer for people and small businesses looking to buy and sell on WhatsApp without having to go to a website, open another app or pay in person. We're rolling the feature out today to a small number of businesses, and it will be available to many more in the coming months," according to Meta. Shares of PagSeguro Digital (PAGS) and StoneCo (STNE), which offer payments services in Brazil, may react to WhatsApp's news. Reference Link

11:27 EDT Carrier up 4% after Journal report on segment spinoff or sale plans - Shares of Carrier Global are up $1.74, or 4%, to $44.04 after The Wall Street Journal said the company is exploring plans to sell or spin off its Fire & Security business.

11:20 EDT 1st Security Bank appoints Ben Crowl to succeed Dennis O'Leary as CLO - 1st Security Bank of Washington has named Ben Crowl to succeed Dennis O'Leary as Chief Lending Officer, effective July 1, 2023. Crowl currently serves as Senior Vice President, Director of Consumer Lending. He previously served the Bank as Senior Vice President, Commercial Lending Team Lead.

11:17 EDT Curiosity enters distribution partnerships across five continents - Curiosity announced key new partnerships helping to expand its global footprint in Asia, Europe, Latin America, North America, and Australia. Recent launch partners include Amazon's Prime Video Channels in India; Telstra- and Astro Malaysia-backed Fetch TV in Australia; The Netherland's largest MVPD, Ziggo, owned by Liberty Global and Vodafone; NLziet, the Dutch streamer operated by the three major Dutch broadcasting groups, NPO, RTL and Talpa; Mexico's Izzi Telecom, owned by Grupo Televisa; and Central and Eastern European distributors MTS, Telekom Slovenia, and Megafon, among others.

10:59 EDT Adaptive Biotechnologies terminates COO Mark Adams - In a regulatory filing, Adaptive Biotechnologies announced that on April 7, COO Mark Adams was informed that his service is being terminated by May 2023. Julie Rubinstein, the company's current President, will absorb the duties of the COO, the company said.

10:36 EDT GM leads $50M funding round in EnergyX - Energy Exploration Technologies, or "EnergyX," and General Motors announced that GM Ventures is leading a $50M Series B financing round in EnergyX, and has entered into a strategic agreement to develop EnergyX's lithium extraction and refinery technology. "The collaboration is focused on unlocking the North American supply of lithium, a critical material for EV batteries, by using EnergyX's innovative process to maximize efficiency while improving sustainability for GM's rapidly scaling EV production," GM stated. Reference Link

10:31 EDT LiveOne expects total memberships to grow to over 3.75M this year - LiveOne's CEO and Chairman, Robert Ellin, commented, "We are seeing robust membership growth having achieved the largest increase in free ad-supported and paid membership since inception of the company. Given this momentum, we expect our total memberships to grow to more than 3.75 million this year."

10:21 EDT High-speed broadband suppliers slide following Adtran warning - Shares of Calix (CALX) and Clearfield (CLFD) are among the stocks tied to high-speed broadband that are falling this morning after Adtran (ADTN) cut its Q1 revenue guidance and warned that the "over-supply condition in CPE products will continue into the second quarter." Adtran cut its Q1 preliminary revenue view to between $322M-$326M as compared to prior guidance of $355M to $375M, stating that the change "was primarily due to customer inventory corrections which impacted our Subscriber Solutions product line." In morning trading, shares of Calix are down $2.14, or 4%, to $53.86, Clearfield's stock has slipped 88c, or 2%, to $46.33 and Adtran shares have plunged $4.16, or nearly 28%, to $10.95.

10:03 EDT Comcast Business provides Oracle Park with WiFi 6E-ready network - Comcast Business (CMCSA) announced that it is providing Oracle Park - the home to the San Francisco Giants - with a fully WiFi 6E-ready network in partnership with Extreme Networks (EXTR). This network refresh will make Oracle Park the first professional sports venue to be completely WiFi 6E-ready. WiFi 6E will improve the connectivity experience by enabling devices to download and upload data from the Internet faster and with lower latency. This means the Giants will be able to improve the fan experience inside the park to include benefits such as fast mobile ticket entry and mobile concessions while considering future innovations like AR/VR experiences and biometrics-based park entry. The 6GHz band adds a significant amount of new spectrum to provide a fast, reliable connection for devices throughout the ballpark. The installation at Oracle Park includes approximately 900 of Extreme's WiFi 6E access points in a combination of overhead and under-seat placements that will provide strong network connectivity for both fans and back-of-house applications throughout the ballpark.

10:01 EDT Cinedigm announces launch of three 'FAST' channels on Amazon Freevee - Cinedigm (CIDM) announced the launch of three free ad-supported streaming television, or "FAST," channels on Amazon (AMZN) Freevee: RetroCrush, The Dove Channel, and Docurama. "These channels join others from Cinedigm's portfolio of streaming brands to be available as free linear channels on Freevee including Realmadrid TV, El Rey, Bob Ross: The Joy of Painting, The Elvis Presley Channel, Midnight Pulp, and the Nacelle Pop Channel," the company stated.

10:00 EDT Calix falls -3.6% - Calix is down -3.6%, or -$2.00 to $54.00.

10:00 EDT Getty Images rises 9.4% - Getty Images is up 9.4%, or 61c to $7.11.

10:00 EDT Brookdale Senior Living rises 24.8% - Brookdale Senior Living is up 24.8%, or 74c to $3.72.

09:57 EDT Calliditas announces publication of cost-effectiveness analysis on Nefecon - Calliditas Therapeutics announced the publication of a cost-effective analysis of Nefecon versus standard of care for people with Primary IgA Nephropathy in the United States. The analysis was published in the peer-reviewed journal ClinicoEconomics and Outcomes Research. Researchers used a health-state transition model to estimate the cost-effectiveness of Nefecon in addition to the SOC versus SOC alone in adult patients with primary IgAN in the US. Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon. Based on commonly accepted willingness to pay thresholds in the US, the research analyzed cost-effectiveness data for Nefecon and demonstrated an incremental cost-effectiveness ratio of $15,428/QALY in a deterministic analysis, likely explained by estimated time spent in less severe stages of kidneys disease.

09:52 EDT Professional Diversity Network trading resumes

09:47 EDT Amprius Technologies falls -4.5% - Amprius Technologies is down -4.5%, or -38c to $8.04.

09:47 EDT Calix falls -5.6% - Calix is down -5.6%, or -$3.15 to $52.85.

09:47 EDT Carvana rises 8.8% - Carvana is up 8.8%, or 81c to $10.12.

09:35 EDT Apollomics Inc trading halted, volatility trading pause

09:26 EDT Diana Shipping enters into time charter contract with IMC Shipping - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/v DSI Drammen, a 2016 built Ultramax dry bulk vessel of 63,379 dwt that the Company entered into an agreement to purchase in February 2023. The Company also announced that, through the same wholly-owned subsidiary, it entered into a time charter contract with IMC Shipping Co. Pte. Ltd., at a gross charter rate of US$18,250 per day, minus a 5% commission paid to third parties, for a period until minimum April 10, 2024 up to maximum June 10, 2024. The charter is expected to commence on April 15, 2023. The employment of "DSI Drammen" is anticipated to generate approximately $6.5 million of gross revenue for the minimum scheduled period of the time charter.

09:23 EDT Kernel Group announces confidential submission of draft registration statement - AIRO Group and Kernel Group Holdings has submitted with the U.S. Securities and Exchange Commission a confidential draft of a registration statement Form S-4 in connection with the proposed business combination between Kernel and AIRO. The closing of the proposed business combination is subject to, among other things, the approval by Kernel's stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions, including a registration statement being declared effective by the SEC, and approval by The Nasdaq Stock Market to list the securities of the combined company. Upon closing of the Transaction, AIRO and Kernel will be wholly-owned subsidiaries of PubCo. PubCo common stock and warrants are expected to be listed on Nasdaq, under the symbols "AIRO" and "AIROW," respectively.

09:20 EDT Getaround, Driver Technologies enter pilot program for dash cam, safety features - Driver Technologies announced a pilot program that will offer drivers of shared vehicles in San Diego, Los Angeles, San Francisco, Portland and Seattle free access to dash cam technology and safety features. Users will have full access to Driver's no. 1 dash cam and safety app, including forward collision, driver drowsiness and distraction alerts, as well as cloud-based video storage, coaching and scoring capabilities. Through the pilot program, which will last for six months, Getaround users who sign up for a Driver account will automatically receive complimentary access to Driver's premium app features for 3-months, which is normally $4.99/month.

09:16 EDT Illumina partners with Henry Ford Health on genomic testing - Illumina and Henry Ford Health, a not-for-profit health care organization in the Detroit metro area, announced the launch of a partnership to assess the impact of comprehensive genomic testing in cardiovascular disease. The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford. The Lisa and Christopher Jeffries Center for Precision Medicine and the Center for Individualized and Genomic Medicine Research at Henry Ford Health will conduct a series of implementation and clinical studies that will investigate the use of next-generation sequencing tests, including whole-genome sequencing, to assess their impact on clinical care. The studies will focus on cardiovascular disease, an area that imposes a substantial clinical and economic burden on the health care ecosystem, with a particular interest in diverse and underserved populations

09:16 EDT Cascadia Acquisition terminates combination agreement with RealWear - Cascadia Acquisition announced that its previously announced business combination agreement with RealWear, Inc. and certain other parties has been terminated in accordance with the terms of the agreement.

09:12 EDT Imperial Petroleum announces full repayment of $30M loan - Imperial Petroleum announced that the Company recently repaid early and in full the $30.0 million outstanding loan with NBG Bank. This loan was secured with first priority mortgages against the Suezmax tankers, the Suez Enchanted and the Suez Protopia. Following this loan repayment, Imperial Petroleum's total debt is in the region of $15 million. The Company currently owns and operates a fleet of twelve vessels, ten of which are unencumbered. The Company elected to voluntarily repay the majority of its outstanding loans so as to utilize its excess cash amidst a positive market environment and shield its cash flow generation going forward against the increasing finance costs.

09:09 EDT Lotus Ventures launches Keylime Kush flower in Ontario - Lotus Ventures announced that its Lotus branded Keylime Kush flower will be available for Ontario retailers to order through the provinces' "Flow Through" program. Retailers can make orders through the Ontario Cannabis Store Wholesale portal to get a first taste of the Lotus Keylime Kush.

09:07 EDT Annovis Bio raises gross proceeds of $8.7M from ATM program, private placement - Annovis Bio announced that in the last week it has raised aggregate gross proceeds of approximately $8.7M between its now-terminated at-the-market program and a private placement to individual members of its Board of Directors and management.

09:07 EDT Mayfair announces latest set of drill results from Fenn-Gib resource expansion - Mayfair Gold announces the latest set of drill results from the Fenn-Gib resource expansion and infill drill program. Mayfair's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario, hosts a NI 43-101 open-pit constrained Indicated Resource of 3.06 million ounces and an Inferred Resource of 0.31M ounces, with disseminated gold mineralization striking east-west on the Pipestone Fault over more than 1.25 kilometers and up to 300 meters wide at the west end. "Wide areas of higher-grade gold mineralization continue to be defined within and below the current conceptual open pit," said Mayfair Gold President and CEO Patrick Evans. "The near-surface, higher-grade mineralization on the west side of the Fenn-Gib deposit opens the potential for a high-grade starter pit. Further expansion drilling below the conceptual open pit is planned to determine the depth extension of the western high-grade zone. Based on assay results received to date, Mayfair is planning to release an updated NI 43-101 resource statement in the second quarter."

09:06 EDT Sprout Social releases Total Economic Impact study conducted by Forrester - Sprout Social announced the release of a Total Economic Impact study conducted by Forrester Consulting that reveals how Sprout Social enabled customers to achieve a return on investment of 233% and a net present value of $1.3 million over three years with a payback period of less than six months. The commissioned study conducted by Forrester Consulting on behalf of Sprout Social found that by eliminating manual work and providing quicker access to key business and consumer insights, Sprout Social enabled customers to boost productivity and focus on building impactful social strategies. The study also found that Sprout Social's customers significantly reduced costs by consolidating their tech stacks and lowering their reliance on paid advertising through organic and employee-driven social campaigns.

09:05 EDT Ball Corp., Loft Federal, Microsoft to collaborate on SDA's NExT program - Ball Aerospace (BALL), Loft Federal and Microsoft (MSFT) announced that they are working together on the Space Development Agency's experimental testbed program, called NExT, that will carry 10 satellites with experimental payloads into orbit. SDA announced the contract award on Oct. 10, 2022. Ball Aerospace is the prime contractor, leading payload and spacecraft integration and test. Ball Aerospace selected Loft Federal to perform spacecraft integration and testing, procure commercial launch services and oversee the launch campaign, and operate the constellation on orbit. Microsoft will provide Azure Government cloud and ground station infrastructure with secure satellite operations post launch as well as productivity solutions to drive mission critical communications.

09:04 EDT Arrival announces 1-for-50 reverse stock split - Arrival announced that, pursuant to the approvals granted at the extraordinary general meeting of shareholders held on April 6, 2023, the Board of Directors has determined to implement a reverse stock split of all of the Company's ordinary shares, having an accounting par value, at a ratio of 1-for-50. The Company is undertaking the reverse stock split with the objective of meeting the minimum $1.00 per Ordinary Share bid requirement for maintaining the listing of the Ordinary Shares on The Nasdaq Global Select Market. At the EGM held on April 6, the Company's shareholders resolved to approve a share consolidation at a consolidation ratio to be set between 1-for-30 and 1-for-50 by the Board of Directors, a share capital reduction without cancellation of shares, and the related amendment to the articles of association. The Board of Directors has been granted the powers to implement these resolutions. The Board of Directors also approved amendments to the articles of association of the Company to reflect the consolidation of the Ordinary Shares pursuant to the Consolidation Ratio.

09:01 EDT Tanger Factory raises annual dividend 11.4% to 98c from 88c per share - Simultaneously, the Board of Directors declared a quarterly cash dividend of 24.5c per share, payable on May 15 to common shareholders of record on April 28.

09:01 EDT Avalon GloboCare signs agreement with Qi Diagnostics - Avalon GloboCare announced that it has signed an agreement with Qi Diagnostics Limited, for exclusive distribution rights to market Qi Diagnostics' KetoAir breathalyzer device and related accessories, including current and future models, in North America, South America, the U.K. and the European Union. KetoAir functions as companion diagnostic and monitoring device for ketogenic dietary management and will initially target the diabetes reversal and weight management markets. "We are very excited to partner with Qi Diagnostics to exclusively distribute the KetoAir in North America, South America, the U.K. and the EU. Our initial go-to-market strategy will target diabetes reversal and obesity management. Increasing clinical evidence has demonstrated that nutritional ketosis is one of the most effective treatment options for sustainably reversing diabetes and weight management. A proper ketogenic diet has been clinically proven to reduce blood sugar, improve insulin sensitivity, and reduce inflammation," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "Being able to safely and consistently maintain nutritional ketosis has been shown to increase the chances of diabetes reversal. KetoAir(TM) is the first breathalyzer on the market that uses an artificial intelligence nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management. It can detect and quantify acetone levels in the breath and monitor the ketosis state, while also providing 24/7 nutritional advice. We look forward to commercializing KetoAir(TM) and helping those individuals with diabetes and weight management needs."

08:52 EDT ISS recommends Bed Bath & Beyond shareholders vote 'FOR' all company proposals - Bed Bath & Beyond announced that Institutional Shareholder Services recommends that Bed Bath & Beyond shareholders vote "FOR" all proposals detailed in the company's definitive proxy statement filed on April 5, 2023. The company's upcoming Special Meeting of Shareholders is scheduled to be held on May 9, 2023 at 10:00 am EDT. In its report dated April 10, 2023, ISS noted the following: The risk to shareholders of non-approval is specific and severe. The reverse stock split may enable the company to raise sufficient equity capital. The company has not demonstrated imprudent use of its authorized shares in the past three years.

08:48 EDT Omniq selected by City of Lumpkin, Georgia to deploy Q Shield VRS technology - OMNIQ has been selected by the City of Lumpkin, Georgia to deploy its Q Shield vehicle recognition systems technology and its cloud based citation management platform.

08:42 EDT ISS recommends Camber Energy shareholders vote for proposed share increase - Camber Energy announced that Institutional Shareholder Services has recommended that Camber shareholders vote "FOR" Proposal 1, as set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on March 10, 2023, in connection with its Special Meeting, which seeks to amend Camber's Articles of Incorporation to increase the number of authorized shares of common stock from 20,000,000 to 500,000,000 shares. ISS has also recommended a vote in favor of Proposal 2 set out in the Proxy. The Special Meeting will be held on April 26th, 2023 at 10:00 a.m. CT.

08:40 EDT Jaguar Health says patient enrollment surpasses 90% in Phase 3 OnTarget trial - Jaguar Health announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. The Company's expectation is that the placebo controlled OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes. The OnTarget trial is evaluating the effectiveness of crofelemer's novel mechanism of action - the modulation of two chloride ion channels in the gastrointestinal tract - to mitigate or substantially reduce chronic cancer therapy-related diarrhea.

08:38 EDT ReShape Lifesciences receives notice of allowance for U.S. patent on Obalon - ReShape Lifesciences announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application 16/792,094, entitled, "Systems and Methods for Determining Failure of Intragastric Devices," related to its Obalon Balloon System. The patent will cover additional claims for the Obalon Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension.

08:35 EDT Sidus Space teams with L3Harris Technologies for DoD mentor-protege program - Sidus Space (SIDU), a Space-as-a-Service company focused on commercial satellite design, manufacture, launch, and data collection, is teaming with L3Harris Technologies (LHX) for the Department of Defense Mentor-Protege Program or MPP. The DoD program helps businesses expand their footprint in the defense industrial base by supporting their partnering efforts with larger companies, such as L3Harris. "We look forward to capitalizing on opportunities for process improvements as we work with L3Harris on various assessments and benchmarking initiatives, gaining valuable large company perspective that will benefit our team as we scale operations in the quarters and years ahead," said Carol Craig, Founder and CEO of Sidus Space. "In addition to expanding our supplier relationship with L3Harris, this agreement will strengthen our ability to provide global customers, including the Department of Defense and other defense agencies, with a range of Space-as-a-Service solutions such as satellite services and space-based data offerings."

08:34 EDT MamaMancini's appoints Joselina Peralta as CPO - MamaMancini's Holdings announced the appointment of Joselina Peralta as the Company's first Chief Procurement Officer and Senior Vice President of End to End Supply Chain. Previously, she served as Global Vice President of Supply Chain & Procurement Operations at Troy Corporation.

08:32 EDT Sigyn Therapeutics announces appointment of Marleau as Chief Scientific Officer - Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, CSO, effective immediately. Dr. Marleau is a recognized thought leader in the development of therapeutic blood purification technologies to address cancer. Prior to joining Sigyn Therapeutics, Dr. Marleau was Chief Technology Officer at Immunicom, where she led R&D endeavors to establish blood purification candidates to treat cancer.

08:32 EDT Hepsiburada regains compliance with Nasdaq minimum bid price requirement - D-MARKET Electronic Services & Trading announced that on April 6, 2023 it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company has regained compliance with the minimum bid price requirement of US$1.00 per share under Nasdaq Listing Rule 5450(a)(1). For the 10 consecutive business days prior to the receipt of the said letter, the closing bid price of the Company's American depositary shares, each representing one Class B ordinary share of the Company, had been trading at US$1.00 per ADS or greater. Nasdaq indicated within the letter that this matter is now closed.

08:27 EDT ZeroFox jumps 84% after announcing Google Cloud partnership - Shares of ZeroFox are up 83.6% or $1.38 in pre-market trading at $3.03 per share. Earlier this morning, the company stated: "Delivering on its mission to make the digital world a safer place, ZeroFox (ZFOX) is partnering with Google Cloud (GOOGL) to disrupt phishing campaigns by quickly warning users of malicious URLs and fake websites. ZeroFox is utilizing the Google Cloud Web Risk Submission API, a service that verifies unsafe URLs and shows warnings across 5 billion devices using browser, social media, and other technology integrations." CEO of ZeroFox states: "Partnering with an industry leader such as Google Cloud to support the Google Cloud Web Risk Submission API further demonstrates that ZeroFox is an innovative leader in protecting organizations beyond the perimeter. External cyber threats are only growing more prevalent as the world becomes increasingly digital, creating an increased need for external cybersecurity. This partnership aligns well with our strategy of partnering with a global network of partners to defend against these threats and accelerate the disruption of malicious actors from hours and days to minutes."

08:24 EDT Uniti Group announces strategic densification of its fiber network - Uniti Group announced the continued strategic densification of its fiber network within several key Southeastern metro markets, providing advanced connectivity solutions to business communities and greater local access opportunities for wholesale customers. Uniti's network, spanning 135,000 route miles and 8 million strand miles of fiber across the U.S., provides world-class communication solutions to enterprise customers, enabling local business communities to fuel continued growth and economic development. The enterprise markets in which Uniti is currently executing its strategic densification plans include Augusta and Columbus, Georgia; Birmingham, Huntsville, Montgomery and Tuscaloosa, Alabama; and Shreveport and Monroe, Louisiana. Uniti plans additional network densification throughout its Southeast footprint in 2023. "Uniti's continued strategic network densification, particularly within our Southeast markets where our brand is already solidly established, will create significant advantages for our enterprise and wholesale customers who continue to face an increasingly competitive environment, with growing bandwidth demands, evolving security threats and aging infrastructure. I'm excited that Uniti is providing the solutions that will help organizations within these communities compete more effectively," said Senior Vice President and Chief Development Officer Cathy De La Garza.

08:23 EDT Rio2 Limited issues shares in lieu of salaries - Rio2 Limited reports that, in accordance with the shares for service agreements announced January 25, 2023 and March 27, 2023, it has agreed to issue 736,151 common shares at a deemed price of $0.15 per share to Directors and Officers of the Company. Under the Shares for Services Agreements, the deemed price per common share to be issued will be no less than the volume weighted average closing price of the Company's common shares on the last three trading days of each quarter, provided that in any event, the price will not be lower than the discount permitted under applicable TSX Venture Exchange policies.

08:22 EDT FOREWARN partners with Greater Alabama MLS - FOREWARN announced that Greater Alabama MLS has contracted to make FOREWARN services available for the 6,500+ members they serve which include the Birmingham Association of REALTORS, Calhoun County Area Board of REALTORS, St. Clair Association of REALTORS, Talladega County Board of REALTORS and the surrounding areas of north-central Alabama, to promote proactive real estate agent safety.

08:21 EDT Saratoga Investment announces BBB+ Investment Grade Rating from Egan-Jones - Saratoga Investment Corp. announced the commencement of a registered public offering of unsecured notes. The Company also announced that it has received an investment grade rating of "BBB+" from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. The Notes are expected to be listed on the New York Stock Exchange and to trade thereon within 30 days of the original issue date under the trading symbol "SAZ". Ladenburg Thalmann & Co. Inc., B. Riley Securities, Inc., and Oppenheimer & Co. Inc. are serving as joint book-running managers for this offering. Compass Point, InspereX LLC, Janney Montgomery Scott LLC and William Blair & Company, L.L.C. are serving as lead managers for this offering. Hovde Group, LLC and Maxim Group LLC are serving as co-managers for this offering. Investors are advised to consider carefully the investment objective, risks and charges and expenses of the Company before investing.

08:19 EDT Panbela regains worldwide rights to develop, commercialize Flynpovi - Panbela Therapeutics announced that it has regained the North American rights to develop and commercialize Flynpovi in patients with familial adenomatous polyposis, FAP, as a result of the termination of the licensing agreement between Cancer Prevention Pharmaceuticals, CPP, and with One-Two Therapeutics Assets Limited. Panbela is now positioned to take the lead on designing the global trial protocol and presenting it to the Federal Drug Administration and European Medicines Agency for agreement on the registration pathway. The new registration trial is expected to focus on FAP patients who have intact lower gastrointestinal anatomy and will build upon the positive results from the FAP-310 trial that were published in the New England Journal of Medicine and Disease of the Colon and Rectum. That study showed 100% risk reduction in the need for surgery in patients with an intact lower gastrointestinal anatomy with Flynpovi vs.CPP-1X or sulindac alone. The Company believes the FAP-310 trial data is compelling and the new registration trial could lead to the approval of Flynpovi. Since there are currently no approved drug therapies for the treatment of FAP, this therapeutic option has the potential to impact this urgent unmet need for patients with FAP globally. "Our focus on disruptive therapeutics for urgent unmet medical needs is at the core of what we do at Panbela. We believe that Flynpovi has the potential to make a meaningful difference for patients with FAP and we are committed to bringing this innovative treatment to market," said Dr. Jennifer Simpson President and CEO of Panbela Therapeutics. "We are excited to regain the worldwide rights to Flynpovi for FAP patients, and believe our internal expertise, experience with health authorities, relationship with FAP experts throughout the US and Europe and our commitment to FAP patients and their families, in combination with the positive results from the FAP-310 trial, provide a solid foundation for designing and executing a successful registration trial that has the potential to impact patients with FAP globally. We plan to advance this program, while maintaining our current cash burn, and will evaluate all opportunities to maximize the value of this asset."

08:17 EDT PSEG appoints Charles McFeaters as Chief Nuclear Officer - PSEG has announced that Eric Carr, PSEG Nuclear president and chief nuclear officer, has accepted a position outside of the company and will be leaving PSEG, effective May 19. Charles "Chaz" McFeaters, PSEG senior vice president Nuclear Operations, will succeed Carr as PSEG Nuclear president and chief nuclear officer. McFeaters has more than 30 years of nuclear industry experience including a loan assignment at the Institute of Nuclear Power Operations. He joined PSEG as site vice president of Salem in 2016 coming from FirstEnergy's (now Energy Harbor) Beaver Valley station. McFeaters was promoted in 2020 to his current role, overseeing the Salem and Hope Creek stations and the training function.

08:16 EDT HII awarded $1.3B contract to support USAFRICOM operations - HII's Mission Technologies division was awarded the $1.3B U.S. Africa Command, USAFRICOM, Personnel Recovery Enterprise Services and Solutions, PRESS, task order. The ASTRO task order, issued by the General Services Administration's Federal Systems Integration and Management, FEDSIM, Center, has a one-year base period with six one-year options. "The PRESS mission goes hand-in-hand with HII's mission to support and deliver all-domain solutions that create the advantage for the Combatant Commands in their mission to protect our national security around the world," said Andy Green, president of Mission Technologies. "We are proud to partner with USAFRICOM to provide life-saving operations to the women and men who serve our nation."

08:15 EDT DermTech in deal with North Carolina Blues plan for foundational assay of DMT - DermTech announced an agreement with a Blues plan in North Carolina. The contract, which is in addition to a favorable coverage policy that became effective March 15, enhances access to the foundational assay of the DermTech Melanoma Test for the more than 3.8M members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value . "We are eager to strengthen our connection with this major payer in North Carolina and further reduce barriers to access with our test now available as an in-network benefit," said Chris Murphy, senior director of payor access, DermTech. "The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are recognizing the value of our test and resulting benefits to their membership, network providers and health plans." DermTech's total covered lives in the U.S. are approximately 126M, which includes 68M for Medicare/Medicare Advantage and 58 million for commercial and governmental payers.

08:13 EDT Agrify announces completion of TTK facility pending final inspection - Agrify Corporation announced that Denver Greens is anticipated to become the new operating partner of Agrify through the acquisition of the total turnkey project Greenstone, pending execution of documentation and final approval from the Colorado Marijuana Enforcement Division. The Agrify TTK Solution is a first-of-its-kind program in which Agrify engages with qualified cannabis operators to provide critical support including: design and buildout of cultivation and extraction facilities, providing state-of-the-art cultivation and extraction equipment, process design, training, implementation, proven grow recipes, product formulations, and data analytics. Phase 1 of major construction is complete at Denver Greens, an approximately 9,000 sq. ft. facility with plans for both cultivation and extraction. Vegetative and mother rooms have been completed and loaded with plant material in anticipation of a spring planting in 60 of Agrify's double-stacked Vertical Farming Units. Final facility approvals are expected by mid-April. Denver Greens recently entered a distribution agreement with Kush Masters, a family run and operated supplier of high-quality cannabis products in the state of Colorado with a reputation of providing products and services since 2014. With this, some of Denver Greens' VFU-grown cannabis will be available on the market as pre-rolled joints and flower in approximately 350 Colorado dispensaries. Additionally, construction plans are being drafted for Phase 2: a facility expansion focused on providing novel SKUs created using Agrify's suite of extraction solutions from iconic brands PurePressure and Precision Extraction Solutions, enabling the creation of both solventless and hydrocarbon extracted products to captivate the Colorado market. It is expected that this project will begin delivering recurring SaaS revenue in q3, 2023, and production success fees in 2024.

08:12 EDT Humacyte completes enrollment in Phase 3 trial of HAV for hemodialysis - Humacyte announced it has completed enrollment of a Phase 3 trial in hemodialysis access. The "V007 Trial" is designed to assess the efficacy and safety of the Human Acellular Vessel in establishing vascular access for hemodialysis patients with end-stage renal disease as compared to autogenous arteriovenous fistulas. The Phase 3 trial, labeled V007, is a prospective, multi-center, randomized, comparative study in 240 hemodialysis patients suffering from ESRD in the United States. "Completing enrollment in this Phase 3 trial brings us one step closer to our goal of providing vascular access for dialysis patients that is usable more quickly after implant and reduces reliance on catheters, compared to AV fistula procedures," said Shamik Parikh MD, Chief Medical Officer at Humacyte. "We believe our regenerative medicine technology has the potential to transform the quality of care nephrologists are able to provide to their patients, and address the substantial failure rate and risk of infection associated with the current AV access options for hemodialysis."

08:10 EDT Eterna, Lincoln Park Capital enter $10M common stock purchase agreement - Eterna Therapeutics announced that the Company has entered into a common stock purchase agreement for up to $10 million with Lincoln Park Capital Fund. Under the terms of the Agreement, LPC has committed to purchase up to $10 million of shares of the Company's common stock at Eterna's sole discretion from time to time during a 24-month period. Commencement of sales under the Agreement is subject to the satisfaction of the conditions in the Agreement, including the effectiveness of a registration statement to be filed by the Company with the Securities and Exchange Commission, registering the resale by LPC of shares to be sold to it under the Purchase Agreement. The sales price per share of the Company's common stock is set forth in the Agreement and is generally based on the market prices prevailing at the time of each sale to LPC. Eterna will retain full control as to the timing and amount of any sale of shares of common stock to LPC under the Agreement, subject to certain limitations specified in the Agreement and those under Nasdaq listing rules. There is no upper limit as to the price per share that LPC may pay for stock issuances under the Purchase Agreement, and LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Eterna's common stock. No warrants are being issued in this transaction, and the Agreement does not contain any rights of first refusal, participation rights, penalties or liquidated damages provisions. Eterna maintains the right to terminate the Agreement at any time, at its discretion, without any cost or penalty.

08:10 EDT MAIA Biotechnology reports topline data from Part A of THIO-101 trial - MAIA Biotechnology announced topline data from the completed Part A safety lead-in of the company's THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer, or NSCLC, and has commenced recruitment in Part B randomized efficacy/dose selection. Topline data from Part A demonstrated that MAIA's telomere-targeting agent, THIO, administered in sequential combination with Regeneron's anti-PD-1 therapy, Libtayo, were generally well-tolerated. No dose-limiting toxicities, or DLTs, or significant treatment-related adverse events were observed. Part A was designed to assess the safety and tolerability of the highest dose of 360 mg/cycle in six patients. Mild toxicities, such as grade 1 fatigue, and muscle pain, were reported, as well as only one occurrence of grade 3 nausea, but no grade 4 adverse events, reported. Part B of the study will allow randomization of patients to three THIO dose levels, including 60 mg, 180 mg and 360 mg, followed by cemiplimab treatment every 3 weeks. Safety and tolerability will continue to be monitored across all THIO doses. The objective of Part B is to determine the most efficacious and safe dose, which will guide Part C of the trial.

08:09 EDT Applied UV names Eugene Burleson chairman, Max Munn CEO - Applied UV announces the following leadership appointments following the completion of Applied UV's acquisition of Puro Lighting and LED Supply . Eugene Burleson who has served on Applied UV's Board of Directors since 2020 has been named Chairman of the Board. Max Munn, the Company's Founder, and a member of the Board of Directors and, has been serving as the interim CEO, has been appointed CEO and President of Applied UV. Brian Stern, chief executive officer and co-founder of PURO, and Andrew Lawrence, chief operating officer and co-founder of PURO and LED Supply have joined the Company's management team.

08:08 EDT Stryve Foods announces brand expansion of Vacadillos through 7-Eleven - Stryve Foods continues to expand distribution nationwide. Vacadillos is capitalizing on its momentum and has expanded its presence with the rollout of its newest products. Vacadillos' newest flavor of Carne Seca, Chipotle Honey, is seasoned with bold flavors using ingredients that consumers know. These thinly sliced strips of flavorful steak, air-dried and seasoned to perfection, bring the ultimate blend of sweet and heat to the franchise. In addition, the Company's research and development team has created NEW air-dried meat sticks in popular Chili Lime and Habanero flavors All three items are now available nationwide at leading convenience store chain, 7-Eleven, in a feature display dedicated to the brand.

08:07 EDT MSG Entertainment announces 'Sphere Experiences' to open this fall - MSG Entertainment announced "Sphere Experiences," one of the core content categories to be featured at Sphere, the company's next-generation entertainment medium opening this fall in Las Vegas. Sphere Experiences will launch this fall with an immersive production - Postcard from Earth. Audiences can be among the first to experience the new world of Sphere when tickets for Postcard from Earth go on sale on Wednesday, April 12.

08:06 EDT Ryvyl experiences growing demand for its BaaS solution - RYVYL announced the Company's innovative Banking-as-a-Service, BaaS, solution is experiencing rapid growth. Six global financial institutions have already signed up as partners and are projected to process more than $100 million in monthly transactions through the BaaS infrastructure when fully ramped up. The new partnerships includes Paydek, one of the leading corporate payment providers in the world; Xace, a banking alternative for the gaming sector; DBank, an international banking institution; JN Bank, a Foreign Exchange bank; Fundstr, a payment solution for businesses and individuals; and Commonwealth Bank & Trust. "RYVYL removes the middleman in many traditional banking operations and allows corporations to conduct the volume of business they need to, in a way that's still fast, easy, and secure," says Fredi Nisan, RYVYL Co-Founder and Chief Executive Officer. "BaaS is the future of global banking, and we're excited to be an enabling service provider in a space that rapidly emerging and reaching new customers every day."

08:05 EDT IN8bio to present new data from Phase 1 trial of INB-100 at EBMT meeting - IN8bio announced that new data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation, HSCT, will be presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation, EBMT, being held in Paris, France April 23-26. Four patients received dose level 1 of INB-100 and two patients received DL2 as of the abstract data cutoff of December 18, 2022. All four patients who received DL1 remain on study and in durable complete remission, with one patient remaining progression free for nearly three years at 32.2 months and the others remaining progression free for 29.8, 18.1 and 3.8 months respectively. Immune system reconstitution through the first 100-days post-treatment was robust and durable, with observed elevations in T cells, NK cells, and gamma-delta T cells. Updated data from this Phase 1 study will be presented at the meeting on April 23rd, 2023.

08:04 EDT ShockWave Medical completes acquisition of Neovasc - Shockwave Medical announced the completion of its previously announced acquisition of Neovasc. The Neovasc Reducer System is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a patient suffers chest pain that cannot be controlled by conventional therapies. It is estimated that each year, in the United States and the European Union alone, up to 300,000 new patients with obstructive coronary disease who are ineligible for conventional revascularization experience refractory angina, despite guideline-directed medical therapy. In addition, it is estimated that up to another 500,000 new patients present with angina and non-obstructive coronary artery disease in the U.S. and the E.U. each year. The Reducer has been granted Breakthrough Device designation by the Food and Drug Administration is CE-marked and is currently enrolling patients in the COSIRA-II study, a randomized clinical trial being conducted under an Investigation Device Exemption intended to support FDA approval for patients with coronary obstructive refractory angina. Shockwave has acquired all of the outstanding common shares of Neovasc for US$27.25 per share in cash upfront by way of a statutory plan of arrangement. Consideration for the purchased shares has been paid to Computershare Investor Services Inc. as depositary under the arrangement and will be provided to former shareholders of Neovasc as soon as reasonably practicable after the date hereof, in accordance with the terms of the arrangement agreement and subject to the ruling by the Israel Tax Authority issued in connection with the Arrangement as described below. In addition, the Shareholders will also receive a potential deferred payment in the form of a non-tradeable contingent value right entitling the Shareholders to receive up to an additional US$12.00 per share in cash if certain regulatory milestones are achieved within specified timeframes. As a result of the completion of the Arrangement, Neovasc's Common Shares will be delisted from the Toronto Stock Exchange. Neovasc has also requested that the Nasdaq Stock Market LLC file a delisting application on Form 25 to report the delisting of the Common Shares of Neovasc from Nasdaq. An application will be made for Neovasc to cease to be a reporting issuer in the applicable Canadian jurisdictions as a result of completion of the Arrangement. Neovasc expects to terminate the registration of its Common Shares under the U.S. Securities Exchange Act of 1934, as amended, approximately 10 days after the closing of the transaction.

08:04 EDT Kura Sushi down 3% in pre-market at $55.25 after pricing $56M stock offering

08:03 EDT Univar selected as exclusive distribution partner of PATcat - Univar Solutions announced its selection as Patcham USA exclusive distribution partner of PATcat metal catalysts in the United States. Patcham's metal catalysts, both tin and tin-free, are used to improve the properties of polyurethane systems and will complement Univar Solutions' strong polyurethane additives portfolio. Univar Solutions Named Exclusive Distributor of Patcham USA"We're excited to work closely with Patcham and appreciate the trust placed in Univar Solutions," said Chris Fitzgerald, global vice president, CASE, Rubber and Plastic Additives for Univar Solutions. "With this agreement for PATcat catalysts, not only are we enhancing our versatile, high-performance polyurethane systems product line, but more importantly we're providing customers access to our extensive sales team, application-specific technical support, and broad complementary product portfolio, helping drive new growth opportunities."

08:02 EDT Vimeo appoints Carter as first Chief Information Officer - Vimeo (VMEO) announced the appointment of Mark Carter as Chief Information Security Officer. Carter has 25 years of extensive technical and SaaS experience, including serving as the Executive Vice President of Security at Salesforce (CRM). He will oversee security, compliance, and risk management at Vimeo.

08:01 EDT Chinook Therapeutics announces voluntary pause in dosing o CHK-336 - Chinook Therapeutics announced that dosing in the phase 1 clinical trial of CHK-336 in healthy volunteers has been voluntarily paused to allow a thorough investigation of a serious adverse event that occurred in a single subject following the first dose in the 125 mg multiple ascending dose group. Dosing was halted per trial protocol when the event occurred, followed by a voluntary pausing of the trial by Chinook to enable further investigation. The event has been reported to the U.S. Food and Drug Administration through a Suspected Unexpected Severe Adverse Reaction report. The SAE had a rapid onset and rapid recovery; follow-up of the subject is ongoing. Based on evaluation to date with input from expert consultants, the underlying cause of the event is being investigated as a potential hypersensitivity reaction to the study drug or its excipients. Next steps will be determined once Chinook and the trial's Safety Monitoring Committee have reviewed all safety data.

07:58 EDT BIO-key says Dayton Children's Hospital to use PortalGuard IDaaS platform - BIO-key announced that its longstanding customer Dayton Children's Hospital will add BIO-key's PortalGuard IDaaS platform to expand its existing BIO-key biometric authentication investment as it migrates from Epic Systems' legacy Hyperspace application to the new browser-based Hyperdrive end-user application interface.

07:58 EDT HUB Security appoints David Riker as Global COO - HUB Cyber Security announced that it has appointed David Riker as its Global COO. As HUB Security's new COO, Riker will lead efforts to scale the Company's global business operations and go-to-market strategies, aligning the Company's two business units, Confidential Computing and Professional Services. Riker will report directly to HUB Security's CEO, Uzi Moskovich. David Riker has over 20 years of experience leading fast-growing technology and risk management companies. Prior to his role at HUB Security, he served as Vice President of Strategic Development at global intelligence leader WorldAware after the sale of BlueLine Grid, a government technology business he founded and led as CEO. Mr. Riker previously served as Managing Director at Kroll, the global risk management company, VP of Products and Corporate Development at Marsh & McLennan and Chief Technology Strategist at Travelers. He was also an operating partner at Pacific Growth Investors, a private equity fund based in Los Angeles, and served as CEO of high growth venture technology startups Storm Exchange and eCoverage.

07:51 EDT CarMax jumps 7% to $70.60 after Q4 EPS beats estimates

07:39 EDT ARway.ai launches Referral Partner Program - ARway.ai announces the Company has launched its Referral Partner Program as part of its business development efforts. The Referral Partner Program will increase ARway's prospect funnel which is expected to lead to accelerating revenue growth. ARway is also preparing to release a Strategic Alliance Partner Program in the near future. This program will create a structure for working with software companies and service providers that wish to integrate their solutions with ARway's or provide add-on services that increase the value of ARway's offerings. It will also provide a framework for coordinating sales and marketing efforts. In addition, ARway has signed The TRIBE - SDK Partner for a first annual partner licence to its new pricing plan on the first tier.

07:37 EDT GameSquare Holdings completes plan of arrangement - GameSquare Holdings has completed its previously announced plan of arrangement with GameSquare Esports, resulting in the Company acquiring all of the issued and outstanding securities of GSQ. As a result of the completion of the Arrangement, GSQ common shares have been halted from trading on the Canadian Securities Exchange and will be subsequently delisted. The combined entity is now known as GameSquare Holdings, Inc. with shares traded on the Nasdaq Capital Market and TSX Venture Exchange under the ticker symbol GAME.

07:35 EDT Safe Harbor reports Q1 monthly average number of accounts 1018 - Q1 2023 Performance:: Monthly average number of accounts held with our financial institution clients increased 75% to 1018, compared to 581 in 1Q22; Monthly average deposit fees increased 49% to $706,728, compared to $475,829 in 1Q22; Monthly average balances on deposit held with our financial institution clients increased 57% to $222.9M, compared to $141.8M in 1Q22; Monthly average deposits held with our financial institution clients increased 33% to $359.1M, compared to $269.5M in 1Q22. "Our performance thus far demonstrates both impressive year-over-year growth and underscores the potential stakeholder value we can build in 2023 and beyond," said Sundie Seefried, CEO. "Executing on each of these metrics has a compounding effect on our business: increasing the number of accounts held with our financial institution clients translates to an expanding national footprint, while growing deposit fee income supports continued cash flow generation from operations. Finally, the remarkable growth in deposit balances held with our financial institution clients will enable us to execute on our lending strategy, which we expect will, in turn, increase both our profitability and customer retention rates. We are confident that this flywheel effect will be a key business driver for years to come, and we are looking forward to building on this momentum with new financial product and service offerings."

07:32 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on April 7, 2023, the compensation committee of BridgeBio's board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan.

07:31 EDT Altimmune completes enrollment in Phase 2 trial of HepTcell - Altimmun announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B. With the achievement of this milestone, data readout is planned for the first quarter of 2024. The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen. "We are pleased to have achieved this milestone in the HepTcell Phase 2 trial and look forward to the data readout in Q1 2024," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "In addition, we look forward to initiating our Phase 2b biopsy non-alcoholic steatohepatitis (NASH) trial in mid-2023 and announcing topline data from our 48-week MOMENTUM obesity trial in the fourth quarter of 2023."

07:27 EDT Spectral AI to be listed on Nasdaq through Rosecliff Acquisition I combination - Spectral MD, an AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces it has entered into a business combination agreement to combine with Rosecliff Acquisition I (RCLF), a special purpose acquisition company listed on Nasdaq. Upon completion of the transaction, the combined company expects to operate under the expected name Spectral AI and to be listed on Nasdaq under the symbol (MDAI). Following the completion of the proposed transaction, the combined company will operate under the same management team, led by founder and CEO Wensheng Fan with current Spectral MD shareholders rolling 100% of their equity into the transaction. The proposed transaction is expected to provide the combined company with improved access to new sources of capital, accelerate readiness for material potential U.S. federal procurement contracts, and enhance company efforts for broad commercialization opportunities of its AI Wound Diagnostics Technology in the U.S., EU and U.K., including both burn and DFU indications, 3-D wound measurement, and digital wound assessment. The proposed transaction is expected to deliver gross proceeds to Spectral MD in excess of $20M. This includes approximately $4.5M held in Rosecliff's trust and an expected private placement investment of no less than $15M. The transaction is not subject to any minimum cash condition and neither (a) minimum cash in trust or (b) any minimum PIPE financing is a condition to closing. The proposed transaction values Spectral MD at an estimated enterprise value of $170M, equivalent to approximately 101p per share on the AIM market. The proposed transaction was unanimously approved by the boards of directors of both parties and is supported by irrevocable proxies and voting agreements of existing shareholders of Spectral MD holding greater than 50% of the outstanding shares. The proposed transaction is expected to be completed in Q3, subject to, among other things, the approval by Rosecliff stockholders and Spectral MD shareholders and the satisfaction or waiver of other customary closing conditions. The newly listed entity Spectral AI will maintain its headquarters at the current office of Spectral MD in Dallas, Texas along with current operations in the U.K. and clinical testing in the U.K. and EU. As part of the proposed transaction, Spectral MD intends to cancel the admission of its common stock to trading on the AIM market of the London Stock Exchange, subject to shareholder approval. Following the delisting, all public trading of securities of the company are expected to take place on Nasdaq. Rosecliff's current stockholders currently hold 8.4M warrants, exercisable at $11.50 per share, which could provide up to an additional $97M of cash to the company depending on the company's stock price following closing of the transaction. Certain of Rosecliff's expenses relating to the transaction are capped at $3.25M. Whereas the company's board of directors is confident the proposed transaction will be consummated on a timely basis, there can be no assurances that the proposed transaction will be completed on the expected timeframe or at all and there can be no certainty in this regard.

07:20 EDT Quince rejects Echo Lake Capital's $1.60 per share acquisition offer - Quince Therapeutics announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash. Following careful review and evaluation, the Quince Board concluded that Echo Lake Capital's proposal undervalues the company and is not in the best interest of Quince and its shareholders.

07:18 EDT Fury Gold Mines announces 2023 Eau Claire exploration program - Fury Gold Mines provides an update on exploration plans for the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. In 2023, the Company plans to drill between 15,000 and 20,000 metres at the project with the goals of continuing expansion of the high-grade Eau Claire resource; following up on the 2022 success at the Percival Prospect 14 kilometres (km) to the east of Eau Claire; and advancing several early-stage exploration targets along the Cannard Deformation Zone to the drill ready stage. "Following a highly successful drill program in 2022, we are excited to be returning to the Eau Claire resource and Percival Prospect. Our goal is to continue to expand the Eau Claire resource, which we know is open in all directions, while also looking for new discoveries elsewhere on the Eau Claire land package which we believe are possible at the Percival Prospect and to the East at our new targets discovered along the Cannard Deformation Zone," commented Tim Clark, CEO of Fury. "Additionally, we are thrilled that Fury will start the year with C$16.2 million in the treasury and about C$60 million in current value in shares in Dolly Varden Silver, which arguably makes Fury one of the best-financed juniors in the sector."

07:16 EDT Moderna sees 2027 respiratory product sales $8B-$15B - The Company estimates respiratory product sales in 2027 to be in the range of $8 billion to $15 billion with corresponding Respiratory operating profit in the range of $4 billion to $9 billion. This framework is supported by $6 billion to $8 billion of additional research and development investments over the next few years. Of note, these estimates are for the respiratory vaccine business only and do not include forecasts for other Moderna products or investments.

07:14 EDT Moderna says DSMB recommends continuation of efficacy followup for mRNA-1010 - The Company's first vaccine candidate against influenza is mRNA-1010, which is being developed in adults. mRNA-1010 is currently being evaluated in two Phase 3 trials. The first Phase 3 trial was conducted in the Southern Hemisphere to evaluate safety and non-inferior immunogenicity compared to a licensed flu vaccine. The previously announced interim results from the P301 trial indicated that mRNA-1010 demonstrated superiority in geometric mean titers for A/H3N2 and non-inferiority in GMT for A/H1N1. mRNA-1010 did not meet non-inferiority for both influenza B/Victoria- and B/Yamagata-lineage strains. mRNA-1010 demonstrated an acceptable safety and tolerability profile in the trial, and the independent Data and Safety Monitoring Board for P301 did not identify any safety concerns. The second Phase 3 trial is being conducted in the Northern Hemisphere to evaluate safety and non-inferior efficacy compared to a licensed flu vaccine. The independent DSMB has completed the first interim analysis of efficacy and informed the Company that mRNA-1010 did not meet the statistical threshold necessary to declare early success and recommended that the trial continue with efficacy follow-up towards the next analysis. The DSMB did not identify any safety concerns. Blinded follow-up for safety and efficacy is ongoing in this trial. A preliminary analysis of immunogenicity from a subset of participants in the P302 trial has also been completed. In this analysis, mRNA-1010 demonstrated geometric mean titer ratios consistent with superiority against both influenza A strains and consistent with non-inferiority against both influenza B strains relative to the licensed comparator. The P302 study did not pre-specify success criteria for immunogenicity endpoints. The Company has developed an update to mRNA-1010 that is expected to have improved immunogenicity against influenza B strains and announced plans to initiate a confirmatory Phase 3 trial this month.

07:11 EDT RedHill Biopharma regains compliance with Nasdaq listing rules - RedHill Biopharma received confirmation from The Nasdaq Stock Market that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450 for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5450, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on April 5, 2023.

07:09 EDT Solaris Resources discovers new porphyry southwest of Warintza Central - Solaris Resources reports that ongoing field work within the Warintza porphyry cluster has identified a new, potentially well mineralized porphyry called Patrimonio, immediately southwest of the Central deposit at its Warintza Project in southeastern Ecuador. Highlights: Patrimonio was discovered via reconnaissance mapping and sampling in an area that had not previously been accessed southwest of Warintza Central, with the northern extent of the target found just outside the Mineral Resource Estimate shell; Patrimonio is defined by highly anomalous sampling over a 1.5km long x 0.6km wide area where outcropping porphyritic diorite displays intense, pervasive biotite alteration and stockwork veining on the western side of a major north-south fault adjacent to Warintza Central; Rock chip samples from weathered outcrop at Patrimonio returned values of up to 1.6% copper, 630 parts per million molybdenum and 0.16 grams per tonne gold; Soil samples at Patrimonio average 764 ppm Cu and 89 ppm Mo, comparable in copper values to Warintza East and Warintza Central, with lower molybdenum values than Central; Together with high-level alteration assemblages observed in outcrop, this metal zonation implies Patrimonio is better preserved/less eroded than Central on the opposite side of the fault, but with similar stockwork veining suggesting the porphyry may be well mineralized; Field crews have established locations for the construction of an initial four drilling platforms in the northern half of Patrimonio, with the first drill hole at the northernmost platform expected to commence later this month; MRE drilling program continues: the 2022 MRE is based on drilling to the end of 2021, with ongoing drilling aimed at expanding the 'Indicative Starter Pit' and overall mineral resources. Jorge Fierro, Vice President, Exploration, commented: "As drilling continues to expand the MRE, we have conducted a program of reconnaissance mapping and sampling that extends into previously inaccessible areas. The discoveries made to date within the Warintza cluster were based largely on sampling work that dates back more than 20 years. The aim of this ongoing effort is to identify targets for high value growth, such as at Patrimonio, where we've discovered a sizeable porphyry target with potential for high grades close to surface in close proximity to our growing MRE."

07:08 EDT Regenxbio receives fast track designation for RGX-202 from FDA - REGENXBIO announced that the FDA has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy. Fast Track designation aims to facilitate the development and expedite the review of new therapeutics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA and may qualify for priority review. The FDA has granted RGX-202 Orphan Drug Designation and Rare Pediatric Disease Designation.

07:06 EDT Sangoma Technologies appoints Moretti to board of directors - Sangoma Technologies Corporation announced the appointment of Joanne Moretti as the Company's first go-to-market expert and female director to sit on the board, effective immediately. Moretti is the current Chief Revenue Officer at Fictiv, the operating system for custom manufacturing.

07:06 EDT Akoustis starts sampling A10159 C-V2X filter solution - Akoustis Technologies has started sampling a new C-V2X filter solution, the A10159, designed for use at 5.9 GHz covering band 47. The filter is currently being sampled and is expected to ramp production in Q4 of calendar 2023.

07:05 EDT Lithium Ionic reports assay results from Galvani claims - Lithium Ionic reports assay results from its Galvani claims as part of an ongoing 30,000 metre drill program, which is expected to culminate with an initial mineral resource estimate, expected in Q2 2023. The Company has to date completed 23,000 metres of drilling at the Bandeira and Galvani properties, which together cover only 872 of the 14,182 hectares it controls in this lithium-producing district. The Galvani claims, acquired in late 2022, are located approximately 5 kilometres northwest of its Bandeira property and Companhia Brasileira de Litio's Cachoeira lithium mine, and approximately 4 kilometres West of Sigma Lithium's large Xuxa lithium deposit. Galvani Drill Intercept Highlights: 1.87% Li2O over 45m, incl. 2.27% Li2O over 4m, 2.87% Li2O over 7m, 2.14% Li2O over 10m, intersected at approximately 30 to 75 metres down-hole and only 20 metres from surface represents the best hole drilled to date at Galvani; 2.10% Li2O over 19.4m, incl. 3.15% Li2O over 6m; 1.48% Li2O over 16.7m; 1.23% Li2O over 17m. Blake Hylands, P.Geo., Chief Executive Officer of Lithium Ionic, commented, "The Galvani target, and our properties extending from it, show huge exploration potential and remain a key focus for our future campaigns. As we work towards completing the infill and definition drilling program at Galvani, the latest results reaffirm the continuity and scale of the large mineralized pegmatites at this target. With the results from the Galvani and Bandeira properties, we are very optimistic about delivering a sizable and high-grade mineral resource estimate in the near-term, as an initial step to delineating much larger resources for significant future growth."

07:04 EDT Acurx: FDA accepts plan for ongoing Phase 2b ibezapolstat clinical trial - Acurx Pharmaceuticals announced that the FDA has accepted the company's plan to have an Independent Data Monitoring Committee conduct an interim review of clinical outcome from the ongoing Ph2b clinical trial of patients with C. difficile Infection. The interim review will be conducted upon reaching enrollment of 36 patients in total. FDA's acceptance was based on the company's filing of a protocol amendment to its Investigational New Drug Application with FDA in January 2023. The company's filing and intention for the IDMC to conduct an interim review of data was based on the observed blinded data to date from the ongoing Ph2b clinical trial at that time. Upon conducting the interim review, the IDMC will determine and recommend to the company whether the most appropriate course of action is to terminate the Ph2b clinical trial early due to success, as the company had done with the Ph2a clinical trial, or to continue patient enrollment. The company intends to report available data promptly after the IDMC conducts this interim review. The IDMC initial organizational meeting was conducted in March 2023 and it has completed all organizational matters required to ensure readiness for data review.

06:53 EDT CarMax reports Q4 total retail used units sold decreased 12.6% - Retail used unit sales declined 12.6% in the fourth quarter, and comparable store used unit sales declined 14.1%; wholesale units declined 19.3% in the fourth quarter. Bought 262,000 vehicles from consumers and dealers, down 22.5% versus last year's record fourth quarter and sequentially up 10.1% from this year's third quarter. CarMax's share of the nationwide age 0-10 year old used vehicle market remained at 4.0% in calendar year 2022. Gains in the first half of the year were offset in the back half, reflecting our focus on achieving profitable market share gains.

06:51 EDT CarMax reaffirms long-term targets - "We affirm our long-term financial targets that we updated in April 2022: (i) selling between 2 million and 2.4 million vehicles through our combined retail and wholesale channels by fiscal 2026 (ii) generating between $33 billion and $45 billion in revenue by fiscal 2026 and (iii) growing our nationwide share of the age 0-10 used vehicle market to more than 5% by the end of calendar 2025."

06:33 EDT AstraZeneca updates arrangements with Sobi, Sanofi for nirsevimab in U.S. - AstraZeneca (AZN), Swedish Orphan Biovitrum AB, or "Sobi," and Sanofi (SNY) have updated and simplified their contractual arrangements relating to the development and commercialization of nirsevimab in the U.S., AstraZeneca announced. "Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties. Under the updated arrangements, Sobi has entered into a direct relationship with Sanofi, replacing the previous participation agreement with AstraZeneca entered into in November 2018. Under the previous agreement, from the day of the transaction with Sobi, AstraZeneca had to provision the risk adjusted value of the discounted cash flow of future payments to be made to Sobi as a liability. As a result of this simplification agreement, Sanofi will pay royalties to Sobi as US nirsevimab sales arise, and the liability related to future obligations is eliminated. AstraZeneca will record a gain of $0.7 billion, to be recognised in Core Other operating income in 2023. This does not impact AstraZeneca's financial guidance for 2023," the company stated.

06:31 EDT Centogene extends partnership with Takeda - Centogene (CNTG) announced it has extended its partnership with Takeda (TAK) to diagnose patients with Lysosomal Storage Disorders. Under the renewed one-year partnership agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.

06:15 EDT Diversified Healthcare Trust, Office Properties to merge in all-share deal

06:01 EDT Google fined 42.1B won by South Korea for blocking games on One Store - South Korea's Fair Trade Commission has fined Google 42.1 billion won for blocking developers from releasing mobile video games on a Korean competitor platform called One Store. The KFTC said in a statement that Google boosted its market dominance and hurt local app market One Store's revenue and value as a platform, by requiring video game makers to exclusively release their titles on Google Play in exchange for providing in-app exposure between June 2016 and April 2018. Reference Link

05:38 EDT Nordstrom to open Nordstrom Rack in Elk Grove in 2024 - Nordstrom announced plans to open a new Nordstrom Rack in Elk Grove, California. The 25,000 square-foot store will be located in The Ridge Elk Grove. The Ridge Elk Grove is owned by Pappas Investments and managed by its affiliate Inverness Management, and it is located at the southeast corner of Elk Grove Boulevard and Bruceville Road. With the addition of this new location, Nordstrom will operate 64 Nordstrom Rack stores, 23 Nordstrom stores, five Nordstrom Locals and one asos Nordstrom in California. The store is scheduled to open in spring 2024.

05:27 EDT Old National Bancorp provides statement on Louisville tragedy - The company provided an updated statement for media regarding today's Louisville tragedy: "There are no words to adequately describe the sadness and devastation that our Old National family is experiencing as we grieve the tragic loss of our team members and pray for the recovery of all those who were injured," said ONB CEO Jim Ryan.

05:13 EDT Pharming Novartis announces first commercial shipments of Joenja in U.S. - Pharming (PHAR) announced the first commercial shipments of Joenja to patients in the United States. Joenja, an oral, selective PI3Kdelta inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Under the terms of Pharming's 2019 exclusive license agreement with Novartis (NVS) for leniolisib, the corresponding first commercial sale of Joenja triggers a $10M milestone payment by Pharming to Novartis.